BCRX Q2 2022 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M+31.2% YoY

Gross Profit

$65M99.6% margin

Operating Income

-$35M-53.0% margin

Net Income

-$59M-89.8% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+31.3%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$511M

Total Liabilities

$724M

Stockholders' Equity

-$213M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$50M	+31.2%
Gross Profit	$65M	$50M	+31.6%
Operating Income	-$35M	-$30M	-17.4%
Net Income	-$59M	-$43M	-36.3%

Revenue Segments

Product

$65M99%

Royalty

$540,0001%

Collaborative and Other Research and Development

$104,0000%